WO2026060312A1 - Vaccins à arnm pour virus de l'herpès simplex 1 et 2 - Google Patents
Vaccins à arnm pour virus de l'herpès simplex 1 et 2Info
- Publication number
- WO2026060312A1 WO2026060312A1 PCT/US2025/046270 US2025046270W WO2026060312A1 WO 2026060312 A1 WO2026060312 A1 WO 2026060312A1 US 2025046270 W US2025046270 W US 2025046270W WO 2026060312 A1 WO2026060312 A1 WO 2026060312A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- hsv
- composition
- nucleic acid
- lipid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16671—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Communicable Diseases (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
L'invention concerne des compositions et des procédés de traitement ou de prévention du VHS chez un sujet.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202463694032P | 2024-09-12 | 2024-09-12 | |
| US63/694,032 | 2024-09-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2026060312A1 true WO2026060312A1 (fr) | 2026-03-19 |
Family
ID=99101121
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2025/046270 Pending WO2026060312A1 (fr) | 2024-09-12 | 2025-09-12 | Vaccins à arnm pour virus de l'herpès simplex 1 et 2 |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2026060312A1 (fr) |
-
2025
- 2025-09-12 WO PCT/US2025/046270 patent/WO2026060312A1/fr active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230346907A1 (en) | Sexually transmitted disease vaccines | |
| US20230181713A1 (en) | Lassa virus vaccine | |
| JP7635131B2 (ja) | 脂質ナノ粒子の調製方法 | |
| JP2025010575A (ja) | ヒトサイトメガロウイルスワクチン | |
| US11723967B2 (en) | Zika virus vaccine | |
| US20190240317A1 (en) | Hpiv3 rna vaccines | |
| US20200315967A1 (en) | Lipid nanoparticles | |
| WO2017015457A1 (fr) | Vaccin contre le virus ebola | |
| CN118846026A (zh) | 广谱流感病毒疫苗 | |
| CA3041307A1 (fr) | Vaccin contre le cytomegalovirus humain | |
| CN110582304A (zh) | 用于治疗或预防肝脏疾病的rna | |
| CN117731769A (zh) | 用于水痘带状疱疹病毒(vzv)的核酸疫苗 | |
| CN108472354A (zh) | 呼吸道合胞病毒疫苗 | |
| US20250099572A1 (en) | Vaccine compositions | |
| WO2024064965A2 (fr) | Vaccin universel à base d'acide nucléique et ses procédés d'utilisation | |
| WO2026060312A1 (fr) | Vaccins à arnm pour virus de l'herpès simplex 1 et 2 | |
| EP4630562A1 (fr) | Vaccin contre le cancer à base d'acide nucléique et méthodes associées | |
| WO2023161350A1 (fr) | Administration nucléotidique d'une thérapie anticancéreuse | |
| JP2025529906A (ja) | コロナウイルスに対するワクチン | |
| WO2026060311A1 (fr) | Vaccins à arnm pour virus d'epstein-barr (ebv) et maladies provoquées par une infection à ebv | |
| TW202444745A (zh) | 用於治療疾病的組合物和方法 | |
| WO2024233388A2 (fr) | Vaccins contre le sarcome et utilisations associées | |
| EP4562163A1 (fr) | Polynucléotides modifiés pour la régulation temporelle de l'expression | |
| CA3107232A1 (fr) | Compositions et methodes de prevention et/ou de traitement de la covid-19 |